The guidance below reflects general principles for peptide injectables
A few patients were forced to discontinue treatment if the symptoms persisted, and this was unusual
There have also been documented local skin reactions when using GLP-1 RAs, particularly with the long-acting formulations
doi: 10.3389/fendo.2022.863184 Received 26 January 2022 Accepted 01 March 2022 Published 24 March 2022 Volume 13 - 2022 Edited by Indraneel (Indi) Banerjee, The University of Manchester, United Kingdom Reviewed by Finbarr P
Patients seeking support for obesity management in the meantime should speak with their GP, who can refer to NHS Tier 3 weight management services (in line with NICE CG189) or consider currently approved pharmacological options where clinically appropriate
The GIP component adds: Enhanced Insulin Response: Even stronger blood sugar control than GLP-1 alone Better insulin secretion timing Improved insulin sensitivity in tissues Fat Metabolism Effects: GIP receptors exist in fat tissue May influence how body stores and uses fat Potentially increases fat burning Synergistic Appetite Suppression: GIP and GLP-1 together produce greater appetite reduction More potent satiety signals Stronger overall effect This explains why tirzepatide produces 5-7% more weight loss than semaglutidethe dual action is more powerful than GLP-1 alone
